Loxo Oncology Inc (LOXO.OQ)
LOXO.OQ on NASDAQ Stock Exchange Global Market
133.45USD
19 Apr 2018
133.45USD
19 Apr 2018
Change (% chg)
$-0.62 (-0.46%)
$-0.62 (-0.46%)
Prev Close
$134.07
$134.07
Open
$133.20
$133.20
Day's High
$137.82
$137.82
Day's Low
$132.93
$132.93
Volume
80,113
80,113
Avg. Vol
154,260
154,260
52-wk High
$138.53
$138.53
52-wk Low
$42.11
$42.11
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 21.30 | -0.688 |
| Sep '17 | 0.00 | -2.454 | |
| Jun '17 | 0.00 | -1.143 | |
| Mar '17 | 0.00 | -0.956 | |
| FY 2016 | Dec '16 | 0.00 | -1.260 |
| Sep '16 | 0.00 | -0.819 | |
| Jun '16 | 0.00 | -0.773 | |
| Mar '16 | 0.00 | -0.593 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 6 | 18.31 | 37.40 | 0.00 | 0.00 |
| Quarter Ending Sep-18 | 3 | 18.20 | 39.60 | 0.00 | 0.00 |
| Year Ending Dec-18 | 3 | 67.50 | 157.30 | 2.90 | 38.02 |
| Year Ending Dec-19 | 3 | 90.20 | 169.70 | 15.60 | 125.83 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 6 | -0.79 | 0.01 | -1.32 | -1.38 |
| Quarter Ending Sep-18 | 3 | -0.86 | -0.10 | -1.40 | -1.38 |
| Year Ending Dec-18 | 4 | -1.79 | 1.56 | -5.36 | -3.59 |
| Year Ending Dec-19 | 5 | -3.50 | 1.36 | -10.41 | -2.26 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 200.91 | 33.50 | |
| P/E High - Last 5 Yrs. | -- | 289.20 | 46.07 | |
| P/E Low - Last 5 Yrs. | -- | 96.91 | 24.95 | |
| Beta | 2.34 | 0.75 | 0.80 | |
| Price to Sales (TTM) | 189.05 | 139.09 | 7.25 | |
| Price to Book (MRQ) | 10.63 | 20.64 | 5.09 | |
| Price to Tangible Book (MRQ) | 10.65 | 25.50 | 6.62 | |
| Price to Cash Flow (TTM) | -- | 130.26 | 25.50 | |
| % Owned Institutions | -- | 11.26 | 2.24 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.28 | 1.53 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 0.75 | |
| Dividend 5 Year Growth Rate | -- | 1.97 | 3.92 | |
| Payout Ratio(TTM) | -- | 9.05 | 20.54 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 81.71 | 8.68 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 96.34 | 11.19 | |
| Sales - 5 Yr. Growth Rate | -- | 34.26 | 8.22 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 45.37 | -64.57 | 22.73 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -52.15 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 48.47 | 10.28 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 45.82 | 10.41 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.61 | 2.53 |
| Current Ratio (MRQ) | 3.53 | 6.04 | 3.61 |
| LT Debt to Equity (MRQ) | 0.00 | 23.33 | 11.39 |
| Total Debt to Equity (MRQ) | 0.00 | 25.72 | 14.02 |
| Interest Coverage (TTM) | -- | -190.60 | 39.28 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 35.01 | 54.05 | |
| Gross Margin - 5 Yr. Avg. | -- | 55.51 | 52.18 | |
| EBITD Margin (TTM) | -714.89 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -150.51 | 15.90 | |
| Operating Margin (TTM) | -715.47 | -562.45 | 4.09 | |
| Operating Margin - 5 Yr. Avg. | -- | -162.33 | 11.23 | |
| Pre-Tax Margin (TTM) | -698.95 | -534.74 | 4.81 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -168.92 | 11.54 | |
| Net Profit Margin (TTM) | -698.95 | -524.03 | 1.42 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -168.92 | 7.87 | |
| Effective Tax Rate (TTM) | -- | -0.15 | 30.96 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.29 | 24.26 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 361,017 | 24,331,705 | 813,295,447 | |
| Net Income/Employee (TTM) | -2,523,322 | 1,121,504 | 95,590,786 | |
| Receivable Turnover (TTM) | -- | 6.53 | 5.56 | |
| Inventory Turnover (TTM) | -- | 2.32 | 3.44 | |
| Asset Turnover (TTM) | 0.05 | 0.40 | 0.89 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -32.06 | -0.74 | 10.51 | |
| Return on Assets - 5 Yr. Avg. | -- | 0.80 | 11.54 | |
| Return on Investment (TTM) | -43.03 | -0.75 | 13.17 | |
| Return on Investment - 5 Yr. Avg. | -- | 4.16 | 14.94 | |
| Return on Equity (TTM) | -58.57 | -2.86 | 14.98 | |
| Return on Equity - 5 Yr. Avg. | -- | -0.19 | 16.23 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | -53.34 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Loxo Oncology Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
- Loxo, Illumina to partner for diagnostic tool targeting cancer
- UPDATE 1-Loxo, Illumina to partner for diagnostic tool targeting cancer
- Loxo and Illumina in partnership over diagnostic for cancer drug
- Loxo and Illumina in partnership over diagnostic for cancer drug
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 221 |
| Total Shares Held: | 32,775,457 |
| 3 Mo. Net Change: | 140,940 |
| # New Positions: | 10 |
| # Closed Positions: | 0 |
| # Increased Positions: | 18 |
| # Reduced Positions: | 9 |
| # Net Buyers: | 9 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.